Literature DB >> 23034170

Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer.

Chunling Ma1, Qunyuan Zhang, Jian Ye, Fang Wang, Yanping Zhang, Eric Wevers, Theresa Schwartz, Pamela Hunborg, Mark A Varvares, Daniel F Hoft, Eddy C Hsueh, Guangyong Peng.   

Abstract

Understanding and dissecting the role of different subsets of regulatory tumor-infiltrating lymphocytes (TILs) in the immunopathogenesis of individual cancer is a challenge for anti-tumor immunotherapy. High levels of γδ regulatory T cells have been discovered in breast TILs. However, the clinical relevance of these intratumoral γδ T cells is unknown. In this study, γδ T cell populations were analyzed by performing immunohistochemical staining in primary breast cancer tissues from patients with different stages of cancer progression. Retrospective multivariate analyses of the correlations between γδ T cell levels and other prognostic factors and clinical outcomes were completed. We found that γδ T cell infiltration and accumulation in breast tumor sites was a general feature in breast cancer patients. Intratumoral γδ T cell numbers were positively correlated with advanced tumor stages, HER2 expression status, and high lymph node metastasis but inversely correlated with relapse-free survival and overall survival of breast cancer patients. Multivariate and univariate analyses of tumor-infiltrating γδ T cells and other prognostic factors further suggested that intratumoral γδ T cells represented the most significant independent prognostic factor for assessing severity of breast cancer compared with the other known factors. Intratumoral γδ T cells were positively correlated with FOXP3(+) cells and CD4(+) T cells but negatively correlated with CD8(+) T cells in breast cancer tissues. These findings suggest that intratumoral γδ T cells may serve as a valuable and independent prognostic biomarker, as well as a potential therapeutic target for human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23034170      PMCID: PMC4832413          DOI: 10.4049/jimmunol.1201892

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

Review 1.  Immunoregulation in the tissues by gammadelta T cells.

Authors:  Adrian Hayday; Robert Tigelaar
Journal:  Nat Rev Immunol       Date:  2003-03       Impact factor: 53.106

2.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 3.  Molecular aspects of epithelial γδ T cell regulation.

Authors:  Deborah A Witherden; Wendy L Havran
Journal:  Trends Immunol       Date:  2011-04-12       Impact factor: 16.687

4.  Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.

Authors:  Hirohito Kobayashi; Yoshimasa Tanaka; Junji Yagi; Yukinari Osaka; Hayakazu Nakazawa; Takehiko Uchiyama; Nagahiro Minato; Hiroshi Toma
Journal:  Cancer Immunol Immunother       Date:  2006-07-19       Impact factor: 6.968

5.  Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer.

Authors:  Zhengbin Shen; Shuang Zhou; Yanna Wang; Ri-lun Li; Cuiping Zhong; Chunmin Liang; Yihong Sun
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-11       Impact factor: 4.553

6.  Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.

Authors:  Guangyong Peng; Zhong Guo; Yukiko Kiniwa; Kui Shin Voo; Weiyi Peng; Tihui Fu; Daniel Y Wang; Yanchun Li; Helen Y Wang; Rong-Fu Wang
Journal:  Science       Date:  2005-08-26       Impact factor: 47.728

Review 7.  Regulatory T cells and cancer.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Curr Opin Immunol       Date:  2007-02-15       Impact factor: 7.486

Review 8.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Small intestinal CD8+TCRgammadelta+NKG2A+ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease.

Authors:  Govind Bhagat; Afzal J Naiyer; Jayesh G Shah; Jason Harper; Bana Jabri; Timothy C Wang; Peter H R Green; John S Manavalan
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

10.  Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway.

Authors:  Guangyong Peng; Helen Y Wang; Weiyi Peng; Yukiko Kiniwa; Kook Heon Seo; Rong-Fu Wang
Journal:  Immunity       Date:  2007-07-26       Impact factor: 31.745

View more
  81 in total

1.  Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.

Authors:  Edmund K Moon; Raghuveer Ranganathan; Evgeniy Eruslanov; Soyeon Kim; Kheng Newick; Shaun O'Brien; Albert Lo; Xiaojun Liu; Yangbing Zhao; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2015-08-31       Impact factor: 12.531

2.  Assessment of tumor-infiltrating TCRVγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays.

Authors:  Marie Tosolini; Frédéric Pont; Mary Poupot; François Vergez; Marie-Laure Nicolau-Travers; David Vermijlen; Jean-Emmanuel Sarry; Francesco Dieli; Jean-Jacques Fournié
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

3.  Specific recruitment of γδ regulatory T cells in human breast cancer.

Authors:  Jian Ye; Chunling Ma; Fang Wang; Eddy C Hsueh; Karoly Toth; Yi Huang; Wei Mo; Shuai Liu; Bing Han; Mark A Varvares; Daniel F Hoft; Guangyong Peng
Journal:  Cancer Res       Date:  2013-08-19       Impact factor: 12.701

4.  Systemic inflammation: Cancer's long-distance reach to maximize metastasis.

Authors:  Seth B Coffelt; Karin E de Visser
Journal:  Oncoimmunology       Date:  2015-08-17       Impact factor: 8.110

5.  Selective, efficient modulation of activated CD4+ αβT cells by the novel humanized antibody GZ-αβTCR targeting human αβTCR.

Authors:  G Blank; C Welker; J Haarer; M Sterk; S Nadalin; V A C Yañez; T O Joos; A Menrad; D Snell; G LaCorcia; A Königsrainer; R Handgretinger; K Schilbach
Journal:  Bone Marrow Transplant       Date:  2014-11-17       Impact factor: 5.483

6.  Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.

Authors:  Carlos R Gil Del Alcazar; Sung Jin Huh; Muhammad B Ekram; Anne Trinh; Lin L Liu; Francisco Beca; Xiaoyuan Zi; Minsuk Kwak; Helga Bergholtz; Ying Su; Lina Ding; Hege G Russnes; Andrea L Richardson; Kirsten Babski; Elizabeth Min Hui Kim; Charles H McDonnell; Jon Wagner; Ron Rowberry; Gordon J Freeman; Deborah Dillon; Therese Sorlie; Lisa M Coussens; Judy E Garber; Rong Fan; Kristie Bobolis; D Craig Allred; Joon Jeong; So Yeon Park; Franziska Michor; Kornelia Polyak
Journal:  Cancer Discov       Date:  2017-06-26       Impact factor: 39.397

7.  Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer.

Authors:  Jieti Wang; Chao Lin; He Li; Ruochen Li; Yifan Wu; Hao Liu; Heng Zhang; Hongyong He; Weijuan Zhang; Jiejie Xu
Journal:  Oncoimmunology       Date:  2017-07-24       Impact factor: 8.110

Review 8.  γδ T Cells: Unexpected Regulators of Cancer Development and Progression.

Authors:  Christopher Fleming; Samantha Morrissey; Yihua Cai; Jun Yan
Journal:  Trends Cancer       Date:  2017-07-17

9.  Characterization of γδ T cells in patients with non-small cell lung cancer.

Authors:  Yi Bao; Li Guo; Juanfen Mo
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

10.  Tumor-derived γδ regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence.

Authors:  Jian Ye; Chunling Ma; Eddy C Hsueh; Christopher S Eickhoff; Yanping Zhang; Mark A Varvares; Daniel F Hoft; Guangyong Peng
Journal:  J Immunol       Date:  2013-01-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.